<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The symptoms and signs constituting the <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) syndrome have their pathophysiologic origins rooted in a salt-<z:chebi fb="156" ids="39214">avid</z:chebi> renal state mediated by effector hormones of the renin-angiotensin-<z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> and adrenergic <z:mp ids='MP_0008912'>nervous</z:mp> systems </plain></SENT>
<SENT sid="1" pm="."><plain>Controlled clinical trials, conducted over the past decade in patients having minimally to markedly severe symptomatic <z:hpo ids='HP_0001635'>heart failure</z:hpo>, have demonstrated the efficacy of a pharmacologic regimen that interferes with these hormones, including <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> receptor binding with either <z:chebi fb="0" ids="9241">spironolactone</z:chebi> or <z:chebi fb="0" ids="31547">eplerenone</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Potential pathophysiologic mechanisms, which have not hitherto been considered involved for the salutary responses and cardioprotection provided by these <z:chebi fb="0" ids="25354">mineralocorticoid</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi>, are reviewed herein </plain></SENT>
<SENT sid="3" pm="."><plain>In particular, we focus on the less well-recognized impact of <z:chebi fb="2" ids="33567">catecholamines</z:chebi> and <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> on monovalent and divalent cation dyshomeostasis, which leads to <z:hpo ids='HP_0002900'>hypokalemia</z:hpo>, <z:hpo ids='HP_0002917'>hypomagnesemia</z:hpo>, ionized <z:hpo ids='HP_0002901'>hypocalcemia</z:hpo> with <z:hpo ids='HP_0000867'>secondary hyperparathyroidism</z:hpo> and hypozincemia </plain></SENT>
<SENT sid="4" pm="."><plain>Attendant adverse cardiac consequences include a delay in myocardial repolarization with increased propensity for supraventricular and <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, and compromised <z:chebi fb="11" ids="22586">antioxidant</z:chebi> defenses with increased susceptibility to nonischemic <z:mp ids='MP_0010632'>cardiomyocyte necrosis</z:mp> </plain></SENT>
</text></document>